Toronto Dominion Bank bought a new stake in shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,436,900 shares of the company's stock, valued at approximately $14,355,000. Toronto Dominion Bank owned about 6.41% of Oaktree Acquisition Corp. III Life Sciences as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also recently modified their holdings of the company. K2 Principal Fund L.P. bought a new position in shares of Oaktree Acquisition Corp. III Life Sciences during the fourth quarter valued at approximately $1,945,000. Sculptor Capital LP purchased a new position in shares of Oaktree Acquisition Corp. III Life Sciences during the fourth quarter valued at $2,490,000. Lighthouse Investment Partners LLC bought a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at about $3,039,000. Shaolin Capital Management LLC bought a new position in Oaktree Acquisition Corp. III Life Sciences during the 4th quarter worth about $5,478,000. Finally, AQR Arbitrage LLC bought a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the 4th quarter valued at about $19,743,000.
Oaktree Acquisition Corp. III Life Sciences Stock Performance
Shares of NASDAQ OACC remained flat at $10.40 during midday trading on Friday. 709,600 shares of the stock were exchanged, compared to its average volume of 116,105. The company has a 50 day moving average price of $10.27. Oaktree Acquisition Corp. III Life Sciences has a 1 year low of $9.95 and a 1 year high of $10.85.
Oaktree Acquisition Corp. III Life Sciences Profile
(
Free Report)
Oaktree Acquisition Corp. III Life Sciences is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 1995 and is headquartered in Los Angeles, CA.
Read More
Before you consider Oaktree Acquisition Corp. III Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oaktree Acquisition Corp. III Life Sciences wasn't on the list.
While Oaktree Acquisition Corp. III Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
